Skip to content
HomeLatest newsCaring & givingHow Johnson & Johnson and the Stephen Siller Tunnel to Towers Foundation are making a difference for military veterans
Johnson & Johnson Stephen Siller Tunnel to Towers Foundation Tunnel

How Johnson & Johnson and the Stephen Siller Tunnel to Towers Foundation are making a difference for military veterans

Share Article
share to

Support for our nation’s soldiers is part of Johnson & Johnson’s DNA.

In the 1800s, the company was integral to spreading the word about the importance of sterile care for wounds sustained on the battlefield, thanks to its innovations in surgical dressings and sutures. And during the Spanish-American War, Johnson & Johnson did something groundbreaking and continued to pay employees their salaries, and held their positions for them, while they served.

That legacy continues to this day, from policies that make it easier for service members on leave to transition back into their day-to-day lives to partnerships that give them the skills and resources they need to thrive.

Partnerships like the one between Johnson & Johnson and the Stephen Siller Tunnel to Towers Foundation, which was founded in 2001 to help military veterans and first responders and their families.

In honor of the 16th annual Tunnel to Towers 5K Run & Walk on September 24, we’re taking a look at how both organizations have joined forces to be there for service members over the past three years.

Tunnel to Towers infographic

More from Johnson & Johnson

What to know about We All Belong: 2023 DEI Impact Review

The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.

Giving the gift of sight

In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.